SMRITHI JAYASHREE SATHEESHKUMAR

Mrs. SMRITHI JAYASHREE SATHEESHKUMAR

PHD STUDENT, Albert Einstein College of Medicine, Bronx, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MLManju Lekshmy
Manju Lekshmy
DRDhanya C R
Dhanya C R
SMRITHI JAYASHREE SATHEESHKUMARSMRITHI JAYASHREE SATHEESHKUMAR
SMRITHI JAYASHREE SATHEESHKUMAR
JSJanaki Anandavallyamma Sindhurani
Janaki Anandavallyamma Sindhurani
JVJiji Joseph Vandanamthadathil
Jiji Joseph Vandanamthadathil
MMMaya Madhavan
Maya Madhavan
Breast and gynecologic cancers are significant global threats to women’s health and those living with the disease require lifelong physical, financial, and social support from their families, healthcare providers, and society as a whole. Cancer vaccines offer a promising means of inducing long-lasting immune response against the disease. Among various types of cancer vaccines available, peptide vaccines offer an effective strategy to elicit specific anti-tumor immune responses. Peptide vaccines have been developed based on tumor associated antigens (TAAs) and tumor specific neoantigens which can also be of viral origin. Molecular alterations in HER2 and non-HER2 genes are established to be involved in the pathogenesis of female-specific cancers and hence were exploited for the development of peptide vaccines against these diseases, most of which are in the latter stages of clinical trials. However, prophylactic vaccines for viral induced cancers, especially those against Human Papillomavirus (HPV) infection are well established. This review discusses therapeutic and prophylactic approaches for various types of female-specific cancers such as breast cancer and gynecologic cancers with special emphasis on peptide vaccines. We also present a pipeline for the design and evaluation of a multiepitope peptide vaccine that can be active against female-specific cancers.

5 February 2026 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
ADAnkita Dutta
Ankita Dutta
NCNandita Chowdhury
Nandita Chowdhury
ASAkshaya Vijayan Selvarajan
Akshaya Vijayan Selvarajan
PGPayel Guha
Payel Guha
PBPritha Banerjee
Pritha Banerjee
DGDwijit GuhaSarkar
Dwijit GuhaSarkar

7 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ADAnkita Dutta
Ankita Dutta
NCNandita Chowdhury
Nandita Chowdhury
ASAkshaya Vijayan Selvarajan
Akshaya Vijayan Selvarajan
PBPritha Banerjee
Pritha Banerjee
AKAbhirupa Kar
Abhirupa Kar
DGDwijit GuhaSarkar
Dwijit GuhaSarkar
Gallbladder cancer (GBC) while rare worldwide has a high prevalence in India. Pathogenesis is unclear and outcomes poor. Gallbladder cholangiocyte organoids (GCOs) or gallbladder carcinoma organoids (GBCOs) were developed and serially propagated from surgically resected gallbladder tissues with benign or malignant diseases, respectively. Patient derived organoids (PDOs) were derived from 15 normal; 58 inflamed; 12 xanthogranulomatous cholecystitis (XGC); 5 pre-invasive neoplasm and 13 invasive malignant gallbladder pathologies. Protocol optimisation achieved 58% (69/119) success in organoid generation and expansion. Organoids maintained tight junction integrity; P-gp pump and enzymatic activity; preserved tissue-specific gene and protein marker expression; histological features and genetic variations. Cryopreserved organoids from 62 patients with primary tissue and high-quality DNA, RNA and protein derivatives have been banked. In gene expression analyses of tissue, XGC samples clustered with malignant subtypes, separate from benign pathologies. Derived XGC organoids showed a similar clustering. Enriched hallmark pathways in XGC support neoplastic change through chronic inflammation. PDOs generated from different gallbladder pathologies are a promising model to investigate the pathogenesis of GBC. Graphical